Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood

Bone Marrow Transplant. 2016 May;51(5):718-21. doi: 10.1038/bmt.2015.303. Epub 2015 Dec 7.

Authors

C Solano^{1

2}, E Giménez³, J L Piñana¹, V Vinuesa³, S Poujois³, S Zaragoza³, M Calabuig¹, D Navarro^{3

4}

Affiliations

¹ Hematology and Medical Oncology Service, Hospital Clínico Universitario, Fundación INCLIVA, Valencia, Spain.
² Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain.
³ Microbiology Service, Hospital Clínico Universitario, Fundación INCLIVA, Valencia, Spain.
⁴ Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain.

PMID: 26642339
DOI: 10.1038/bmt.2015.303

No abstract available

MeSH terms

Adolescent
Adult
Aged
Antiviral Agents / therapeutic use*
Cytomegalovirus / physiology
Cytomegalovirus Infections / blood*
Cytomegalovirus Infections / drug therapy
DNA, Viral / blood*
Female
Ganciclovir / therapeutic use*
Hematopoietic Stem Cell Transplantation*
Humans
Male
Middle Aged
Transplantation, Homologous
Virus Replication
Young Adult

Substances

Antiviral Agents
DNA, Viral
Ganciclovir